Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced data from the dose ...

Nuvalent, Inc. , a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced preliminary data from the ...

The second phase of the Global Sources Hong Kong Shows opened today at AsiaWorld-Expo, running from October 18 to 21. The four-day event combines four major trade shows: the Mobile Electronics, Smart ...

Vakiav, a technology company specializing in pet care and wildlife observation devices, today announced the release of its first window-mounted smart bird feeder ? the VK-G2. Building on the success ...

Infrrd, a global leader in AI-driven document processing solutions, has announced the official launch of Ally, the company's pioneering Agentic AI workforce built exclusively for the mortgage industry ...

On October 14, the 2025 Global Engineering Conference and the first World Green Design Conference opened in Shanghai, China, drawing together over 250 former senior UN officials, academicians from ...

Darkness to Light, a leading national nonprofit dedicated to preventing child sexual abuse, announced the launch of the 2025 Stewards of Children® Advocacy Awards, expanding its nationwide effort to ...

Pomerantz LLP announces that a class action lawsuit has been filed against Lantheus Holdings, Inc. ("Lantheus" or the "Company") . Such investors are advised to contact Danielle Peyton at ...

Pomerantz LLP is investigating claims on behalf of investors of EHang Holdings Limited ("EHang" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646 ...

Pomerantz LLP is investigating claims on behalf of investors of MoonLake Immunotherapeutics ("Moonlake" or the "Company") . Such investors are advised to contact Danielle Peyton at ...

Pomerantz LLP is investigating claims on behalf of investors of  Synopsys, Inc. ("Synopsys" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581 ...